Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada based contract manufacturing organization QSV Biologics has received a cGMP manufacturing contract for a recombinant protein under development, from Pfizer.
Subscribe to our email newsletter
The protein will be manufactured at QSV’s Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.
Graeme Macaloney, founder, president & CEO of QSV, said: “The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV’s continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer.”